Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist ...

The FDA dealt Lantheus’ bid to garner approval of its radiodiopharmaceutical diagnostic kit a setback due to manufacturing issues at a third-party facility. (Stock Photo ) The FDA dealt Lantheus’ bid ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...

Exelixis’ next franchise in a drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

During her presentation, Moderna’s Das said the company proposed a “modified regulatory framework” during the FDA meeting.

Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since, founder and CEO ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...